antidepressant - MGH Center for Women's Mental Health

Reviewing the Safety of SSRI’s in Pregnancy

Over the past 15 years, multiple studies have addressed the reproductive safety of the selective serotonin reuptake inhibitors (SSRIs). Data on the overall teratogenicity of SSRIs come from relatively small cohort studies and larger international programs, and they have cumulatively supported the reproductive safety of fluoxetine (Prozac) and certain other SSRIs. However, several recent studies have raised concerns regarding the use of SSRIs during pregnancy.

By MGH Center for Women's Mental Health|2015-07-23T14:50:24-04:00December 31st, 2005|Antidepressants, Outcomes, Pregnancy & Medications, Pregnancy Outcomes|Comments Off

Recent Antidepressant Label Changes

In October, the Food and Drug Administration (FDA) ordered drug manufacturers to include warnings in the packaging inserts regarding the use of certain antidepressants, including the selective serotonin reuptake inhibitors (SSRIs) and venlafaxine (Effexor), during pregnancy. The labels now describe a spectrum of adverse events in newborns exposed to these drugs late in the third trimester, including jitteriness, irritability, hypoglycemia (low blood sugar), feeding difficulties, respiratory distress, abnormal muscle tone, and constant crying. Complications requiring “prolonged hospitalization, respiratory support and tube feeding” are also mentioned.

By MGH Center for Women's Mental Health|2015-07-21T12:51:48-04:00April 15th, 2005|Antidepressants, Pregnancy & Medications|Comments Off

Paroxetine and Cognitive-Behavioral Therapy (CBT) for the Treatment of Postpartum Depression (PPD)

Postpartum depression (PPD) is relatively common, occurring in about 10 to 15% of women after delivery. Non-pharmacologic interventions, including interpersonal psychotherapy, have been shown to be effective for the treatment of PPD. In addition, several reports have documented the efficacy of selective serotonin reuptake inhibitors (SSRIs) and the serotonin norepinephrine reuptake inhibitor venlafaxine (Effexor). In a recent report, Misri and colleagues have evaluated whether the addition of Cognitive-Behavioral Therapy (CBT) to standard antidepressant treatment improves outcomes in women with postpartum depression and co-morbid anxiety.

By MGH Center for Women's Mental Health|2015-07-21T11:37:31-04:00September 20th, 2004|Medication, Postpartum Depression, Postpartum Psychiatric Disorders, Psychotherapy, Treatment|Comments Off

Bupropion and Breastfeeding

Data have accumulated over the last few years on the use of antidepressants in nursing mothers. It appears that all antidepressants are secreted into the breast milk; however, the amount of medication to which the nursing child is exposed appears to be relatively small. We have the most information is available for fluoxetine (Prozac), sertraline (Zoloft), paroxetine (Paxil), and the tricyclic antidepressants. In general, one should try to choose an antidepressant for which there are data to support its safety during breastfeeding. However, there are often situations where one may choose another antidepressant that has not been as well characterized. For instance, if a woman has not responded well to any of the above medications.

By MGH Center for Women's Mental Health|2015-07-21T10:41:36-04:00November 6th, 2002|Breastfeeding & Medications, Child Outcomes, Depressive Disorders|Comments Off

Selecting an Antidepressant During Pregnancy

Most women and their doctors try to avoid using medications during pregnancy. Of greatest concern is that a medication used during pregnancy may in some way harm the developing fetus or, at the very worst, cause a birth defect. But what happens when a pregnant woman needs to take a medication?

By MGH Center for Women's Mental Health|2015-07-20T10:15:46-04:00May 6th, 2001|Anxiety Disorders, Child Outcomes, Depressive Disorders, Medication, Pregnancy & Medications, Psychiatric Disorders During Pregnancy, Risk of Malformations, Treatment|Comments Off